In a woman with prior coronary artery disease and stent placement presenting with distal interventricular septal thinning and hypokinesis, what is the likely etiology and how should it be evaluated and managed?

Likely Etiology and Management of Distal Interventricular Septal Thinning and Hypokinesis in a Woman with Prior CAD and Stent

In a woman with prior coronary artery disease and stent placement, distal interventricular septal thinning and hypokinesis most likely represents prior myocardial infarction in the territory of a septal perforator branch or the distal left anterior descending artery, and requires immediate assessment of stent patency, optimization of dual antiplatelet therapy, and evaluation for ongoing ischemia. 1, 2

Etiology Assessment

The distal interventricular septum is primarily supplied by septal perforator branches of the left anterior descending coronary artery, and thinning with hypokinesis indicates transmural myocardial injury from prior infarction 2. In patients with previous stent placement, several mechanisms must be considered:

Stent-Related Complications

• Stent thrombosis (acute, subacute, or late) remains a critical concern, particularly if dual antiplatelet therapy was prematurely discontinued, as this is one of the strongest predictors of stent occlusion 3, 4
• In-stent restenosis can develop months to years after stent placement, though second-generation drug-eluting stents have lower rates 5, 6
• Coronary microvascular dysfunction occurs in approximately 59% of patients after drug-eluting stent implantation even without in-stent restenosis, with both endothelium-dependent and endothelium-independent dysfunction contributing to ongoing ischemia 6

Septal Perforator Disease

• Large septal perforator thrombosis can cause isolated septal infarction presenting with ST-segment elevation in V1-V2, though this is rare 2
• Segmental left ventricular hypokinesis, particularly involving the interventricular septum and apex, is associated with embolic signals in the middle cerebral arteries and may indicate a cardioembolic source 1

Immediate Diagnostic Evaluation

Assess Stent Patency and Ischemia

• Emergency coronary angiography should be performed immediately if acute stent thrombosis is suspected based on new symptoms, troponin elevation, or ECG changes 4
• Stress imaging (adenosine or dipyridamole myocardial perfusion SPECT, PET, CMR, or stress echocardiography) is reasonable for patients with new or worsening symptoms to identify extent and severity of ischemia 3
• Avoid exercise ECG alone in patients with prior stent placement; stress imaging provides superior diagnostic accuracy 3

Evaluate Left Ventricular Function

• Echocardiography is recommended to assess left ventricular ejection fraction, segmental wall motion abnormalities, and exclude complications such as ventricular aneurysm or thrombus 3
• Assessment of left ventricular function guides medical therapy optimization, particularly regarding ACE inhibitor and beta-blocker use 3

Medical Management Optimization

Dual Antiplatelet Therapy

Aspirin 75-100 mg daily must be continued indefinitely in all patients with prior stent placement 3, 4

P2Y12 inhibitor therapy requires careful assessment:

• If within 12 months of drug-eluting stent placement, continue ticagrelor 90 mg twice daily (preferred) or clopidogrel 75 mg daily 3
• Ticagrelor is preferred over clopidogrel in patients at moderate-to-high risk of ischemic events, including those with prior MI or elevated troponins 3
• If beyond 12 months post-stent and patient has high-risk features (left main stenting, multivessel stenting, prior stent thrombosis, or only remaining coronary artery), consider continuation of dual antiplatelet therapy beyond the standard 12-month period 3
• Never discontinue antiplatelet therapy abruptly without consulting the treating cardiologist, as this markedly increases risk of catastrophic stent thrombosis, MI, or death 3

Guideline-Directed Medical Therapy

• High-intensity statin therapy should be initiated or optimized immediately, targeting LDL-C <55 mg/dL with addition of ezetimibe if needed 3
• Beta-blockers are recommended as essential therapy for relieving angina and reducing morbidity and mortality, particularly in patients with prior MI or heart failure 3
• ACE inhibitors (or ARBs if ACE inhibitor intolerant) are recommended in patients with symptomatic heart failure, asymptomatic LV dysfunction following MI, or other conditions including hypertension or diabetes 3
• Mineralocorticoid receptor antagonist should be added if patient remains symptomatic despite adequate treatment with ACE inhibitor and beta-blocker 3

Invasive Management Considerations

Indications for Coronary Angiography

• Immediate angiography is indicated for suspected acute stent thrombosis with hemodynamic instability, ongoing chest pain, or ST-segment elevation 4
• Urgent angiography (<72 hours) is recommended for patients with intermediate-risk criteria including diabetes, renal insufficiency (eGFR <60 mL/min/1.73 m²), LVEF <40%, or recurrent symptoms 3
• Elective angiography is reasonable for patients with marked limitation of ordinary activity (Canadian Cardiovascular Society class III) despite maximal medical therapy 3

Revascularization Techniques

If stent occlusion is confirmed, revascularization should include:

• Thrombus aspiration if significant thrombus burden is present 4
• Balloon angioplasty to restore flow 4
• Additional stenting if needed for residual stenosis or dissection 4

Prevention of Recurrent Events

Medication Adherence

• Patient education on the catastrophic risks of premature antiplatelet therapy discontinuation is crucial 3, 4
• Patients must contact their cardiologist before stopping any antiplatelet therapy, even if instructed by another healthcare provider 3

Surgical Procedure Planning

• Elective surgery should be postponed for at least 1 month after bare-metal stent implantation and 6-12 months after drug-eluting stent implantation 3, 4
• If surgery cannot be deferred, aspirin should be continued throughout the perioperative period if at all possible, and the P2Y12 inhibitor restarted as soon as possible postoperatively 3
• Clopidogrel should be withheld for 5-7 days before elective CABG to minimize bleeding risk 3

Risk Factor Modification

• Aggressive management of cardiovascular risk factors including hypertension, diabetes, smoking cessation, and weight management is necessary 4
• Annual influenza vaccination is recommended 3

Common Pitfalls to Avoid

• Do not assume the septal abnormality is old and stable without evaluating for ongoing ischemia or stent patency 6
• Do not discontinue dual antiplatelet therapy prematurely, as this is the strongest predictor of stent thrombosis 3, 4
• Do not rely on exercise ECG alone in patients with prior stent placement; stress imaging is required 3
• Do not overlook coronary microvascular dysfunction as a cause of persistent symptoms even with patent stents 6